Torrent Pharmaceuticals announced that its Board of Directors has approved the Audited Standalone Financial Results for the quarter and nine months ended December 31, 2025. The Board also declared an interim dividend of ₹29 per equity share (580%), payable on or around March 6, 2026. The company reported strong standalone profitability, with Net Profit rising to ₹577 crores for the quarter.
Financial Results Approval for Q3 FY26
Torrent Pharmaceuticals Limited confirmed that its Board of Directors met on February 13, 2026, to approve key financial outcomes for the third quarter of the fiscal year 2026. The approval covered the Audited Standalone Financial Results for the quarter ending December 31, 2025, along with the associated audit report.
Standalone Financial Performance Highlights (Q3 FY26 vs Q3 FY25)
Standalone performance showed significant year-over-year growth:
- Total Income: Increased from ₹2,380 crores to ₹2,591 crores.
- Total Expenses: Remained controlled, rising to ₹1,824 crores from ₹1,729 crores.
- Profit Before Tax: Improved from ₹651 crores to ₹757 crores.
- Net Profit for the Period: Grew from ₹485 crores to ₹577 crores.
- Earnings Per Share (Basic): Rose to ₹17.04 from ₹14.33 in the corresponding quarter last year.
Nine Months Ended December 31, 2025 Performance
For the nine-month period, the company reported Total Income of ₹7,937 crores, compared to ₹7,266 crores in the prior year period. Net Profit for the nine months stood at ₹1,725 crores, up from ₹1,414 crores previously. Basic EPS for the nine months reached ₹50.96, against ₹41.79 in the nine months ended December 31, 2024.
Interim Dividend Declaration
A significant action taken by the Board was the recommendation of an interim equity dividend. The dividend is set at ₹29/- (580%) per equity share (face value of ₹5 fully paid up). This dividend is scheduled to be paid or dispatched on or around March 6, 2026.
Consolidated Performance Overview (Media Release Highlights)
The accompanying media release provided consolidated highlights, indicating robust growth:
- Q3 FY26 Consolidated Revenue: Reached ₹3,303 crores, an 18% YoY increase.
- Q3 FY26 Operating EBITDA: Stood at ₹1,088 crores, up 19% YoY, yielding an Operating EBITDA margin of 33%.
- Q3 FY26 Net Profit After Tax (PAT): Grew by 26% YoY to ₹635 crores.
- Exceptional Item: The quarter included a negative exceptional item of (₹10 crores), related to regulatory and statutory fees associated with the acquisition of J.B. Chemicals & Pharmaceuticals Ltd.
JB Pharma Acquisition Context
The results reflect the completion of the acquisition of a controlling stake in J.B. Pharma. The company secured control effective from January 21, 2026. The merger scheme process is currently underway, pending requisite regulatory approvals before filing with the NCLT. The results for the current quarter do not include the effect of business combination accounting under Ind AS 103.
International Market Performance (Consolidated Insights)
Key international markets showed expansion:
- India: Revenues up 14%, reaching ₹1,798 crores for the quarter.
- Brazil: Revenues surged by 27% in Rupee terms (or 10% in Constant Currency).
- United States: US business revenues were up 19%, with Constant Currency revenues growing 12% YoY.
- Germany: Revenues grew 8%, though Constant Currency revenues were down 6% due to supply disruption issues.
Regulatory Compliance and Disclosures
All financial results, both standalone and consolidated, are being submitted in compliance with relevant requirements. Furthermore, the Board noted that the incremental impact of the new consolidated labor codes implemented in November 2025 on employee benefits was assessed as not material for the current reporting period.
Source: BSE
